Celgene in the news
Discovering innovative medicines
Tamtam found 20 recent articles about Celgene.
- ANTITRUST—D.N.J.: Revlimid buyers’ pay-for-delay antitrust claims survive drugmakers’ motion to dismiss
A federal court allowed antitrust claims to proceed against Celgene and other drugmakers, alleging their 2015 settlement with Natco Pharma unlawfully delayed generic Revlimid entry and maintained high prices.
- Bristol-Myers, Natco And More Can't Ditch Cancer Drug MDL
A New Jersey federal judge did not dismiss an antitrust lawsuit against Bristol-Myers Squibb, Natco Pharma, and other companies regarding Celgene's cancer drug Revlimid, finding 'pay-for-delay' claims plausible.
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
A judge ruled that Celgene, Teva, and other companies must face US antitrust claims related to Revlimid.
- Celgene Fails to Fend Off Antitrust Claims in Pay-for-Delay Suit
A federal judge allowed an antitrust pay-for-delay lawsuit against Celgene Corp. and Natco Pharma Ltd. to proceed, concerning a settlement that allegedly delayed a generic blood cancer drug and kept prices high.
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
A US judge ruled that Celgene, Teva, and other companies must face antitrust claims for allegedly monopolizing the Revlimid market.
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers Squibb secured accelerated FDA approval for Zenbexus, a multiple myeloma drug acquired from Celgene, demonstrating superior efficacy and projected to achieve over $1 billion in sales by 2031.
- What Does Bristol Myers Squibb (BMY) Risk From The Revived $6.7 Billion Lawsuit?
A federal appeals court reinstated a US$6.7 billion lawsuit against Bristol Myers Squibb concerning its Celgene acquisition, alleging delayed FDA approvals to avoid payouts.
- Bristol Myers Squibb Faces Revival of USD 6.7 Billion Celgene Shareholders' Lawsuit
A US appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over claims it delayed drug approvals to avoid payouts to former Celgene shareholders.
- Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals
Bristol Myers Squibb faces a revived $6.7 billion lawsuit regarding delayed drug approvals, brought by UMB Bank on behalf of former Celgene shareholders.
- US appeals court revives $6.7 billion lawsuit against Bristol Myers Squibb
A U.S. appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb concerning alleged delayed drug approvals affecting payments to former Celgene shareholders.
- Appeals court revives $6.7B lawsuit against Bristol Myers Squibb
Bristol Myers Squibb faces a revived $6.7 billion lawsuit from former Celgene shareholders after an appeals court overturned a lower court's dismissal.
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
Cigna-backed health plans are appealing a dismissed lawsuit against Bristol-Myers Squibb and Celgene, alleging fraudulent patent acquisition and sham litigation to protect a cancer drug from generic competition.
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
Cigna-backed health plans and pharmacies are seeking to revive a lawsuit against Bristol-Myers Squibb and Celgene, alleging fraudulent patent acquisition and sham litigation.
- Celgene Number of Employees 2026 | Employee Count & Headcount Data
Celgene Corp. has 1,379 employees globally as of March 2026, with its workforce declining by 17.5% since 2023 but maintaining positive employee sentiment.
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
Health plans and pharmacies are asking the Second Circuit to revive a class action alleging Bristol-Myers Squibb and Celgene used fraudulent patents and pay-for-delay tactics to monopolize the cancer drug Pomalyst.
- Bristol Myers Squibb stock trades steady as oncology revenue and Celgene legacy shape valuation
Bristol Myers Squibb's stock valuation is driven by strong oncology revenues, the strategic acquisition of Celgene, diversified drug portfolio, and a robust pipeline, even as it navigates patent expirations.
- Scleroderma Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson
DelveInsight's report analyzes the global Scleroderma treatment pipeline, identifying over 50 therapies from 45 companies, including ongoing clinical trials and market drivers and barriers.
- Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics appointed former Celgene executive Corsee Sanders to its board to guide the clinical advancement of its genetic medicine pipeline.
- FDA decision: Iberdomide by Celgene (in 2026)
FDA approval decision for the multiple myeloma drug iberdomide is anticipated in 2026.
- How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'
Bristol Myers Squibb's drug mezigdomide doubled progression-free survival for multiple myeloma patients in a recent clinical trial.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Celgene?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies